全球溶瘤病毒治疗市场-2022-2029

市场概览

溶瘤病毒治疗市场预计在预测期间（2022-2029 年）以 19.32% 的复合年增长率增长。

溶瘤病毒是基因工程或天然存在的病毒，它们模仿选定的术语，可以杀死癌细胞，同时保留正常组织。溶瘤病毒疗法是一种新型的癌症治疗方法，并在全球范围内取得了可喜的成果。

市场动态

癌症患者数量的增加和溶瘤病毒等癌症治疗方法的不断发展正在推动全球市场的增长。

癌症患者的增加和临床研究正在推动全球溶瘤病毒治疗市场的增长。

不断上升的癌症病例和越来越多的溶瘤病毒治疗临床研究正在推动全球市场增长。例如，根据 Clinical Trials.Gov，有 10 项介入性临床研究。根据政府的说法，有 10 项积极的介入临床研究。其中一些正在接受卫理公会医院研究所赞助的立体定向放射治疗和原位溶瘤病毒治疗转移性三阴性乳腺癌和转移性非小细胞肺癌的 II 期失去机会试验，计划于 2023 年进行。到 11 月结束。美国国家癌症研究所 (NCI) 赞助的 Pexavec 溶瘤病毒联合免疫检查点抑製剂治疗难治性结直肠癌的 1/2 期研究（计划于 2023 年 6 月完成），Genelux Inc. 赞助了 1b 期和 2 期研究（ VIRO-15) GL-ONC1 oncortoimmunotherapy 用于復发或难治性卵巢癌患者（预计完成时间：2022 年 12 月）。

此外，据世界卫生组织统计，2020年癌症将导致1000万人死亡，大约六分之一的人将死于癌症。其中，约70%发生在低收入和中等收入国家，最常见的癌症类型是乳腺癌（2020年226万例）、肺癌（2020年约221万例）、结直肠癌（193万例） 2020 年）。

高成本和免疫反应正在抑制市场增长。

由于重复施用癌症治疗药物而对基于病毒的疗法产生的免疫反应已成为製约市场增长的重要因素。溶瘤病毒治疗的高成本将进一步影响市场增长，尤其是在新兴国家。

COVID-19 的影响

COVID-19 通过创造更好的机会对市场产生了积极影响。例如，COVID-19 引导我们专注于生物技术增强产品以获得更好的结果。在大流行期间，许多生物製药行业开发了各种生物技术改进的疫苗来克服大流行，用于治疗和诊断 SARS-CoV-2。此外，生物技术设备在抗击大流行的各个阶段都发挥了作用。 COVID-19 大流行已将目光转向生物技术解决方案，以改善医疗保健系统，这对免疫毒素市场产生了积极影响。

细分分析

预计黑色素瘤细分市场将在预测期内（2022-2029 年）主导全球市场。

黑色素瘤是皮肤黑色素瘤日益严重的负担，FDA 目前正在测试一种单纯疱疹病毒 (HSV) 的溶瘤株，这是一种感染和破坏肿瘤细胞的改良单纯疱疹病毒 (HSV)，用于治疗皮肤黑色素瘤。由于病毒疗法、T-VEC (Imlyg) 等新产品的批准，预计在预测期内（2022-2029 年）它将主导全球市场。根据世界卫生组织的数据，全世界每年有 2 到 300 万例非黑色素瘤皮肤癌和 132,000 例黑色素瘤皮肤癌。根据皮肤癌基金会的统计，五分之一的美国人在其一生中会患上皮肤癌。随着臭氧层的消耗，大气失去了越来越多的保护过滤功能，让更多的太阳紫外线辐射到达地表。据估计，臭氧水平降低 10% 会导致 300,000 多例非黑色素瘤皮肤癌和 4,500 多例黑色素瘤。根据世界癌症研究基金国际组织的数据，皮肤黑色素瘤是世界上第 17 位最常见的癌症，2020 年有超过 150,000 例新发黑色素瘤病例。根据皮肤癌基金会的数据，美国每天有超过 9,500 人被诊断出患有皮肤癌。

区域分析

北美地区拥有世界上最大的溶瘤病毒治疗市场。

北美将在 2021 年主导全球溶瘤皮肤癌市场。由于癌症负担增加、研发重点和支出增加以及北美主要市场参与者的存在，预计该地区将在整个预测期间（2022-2029 年）占据主导地位。根据美国国家癌症中心的数据，2020 年有 1,806,590 人新诊断出患有癌症，有 606,520 人死于癌症。根据美国癌症协会的数据，到 2021 年，将有大约 190 万人被诊断出患有这种疾病，608,570 人将死于这种疾病。疾病预防控制中心预测，到 2040 年，每年将有 2950 万新癌症病例。此外，北美拥有最强大和最先进的医疗基础设施以及更好的医疗报销政策，这有助于北美在预测期内主导全球市场。

竞争格局

溶瘤病毒治疗高度集中在Amgen Inc.、Shanghai Sunway Biotech Co. Ltd、RIGVIR 等少数主要参与者中。该行业的公司以低利润率运营，在预测期内可能会进一步恶化。行业参与者正专注于实施无机增长战略以扩大其市场占有率。例如，2022 年 1 月 11 日，Amgen 和 Arrakis Therapeutics 合作确定了新型 RNA 降解小分子疗法。

Amgen Inc.

概述

Amgen, Inc. 成立于 1980 年，总部位于加利福尼亚州千橡市，是一家领先的跨国生物製药公司。 Amgen 专注于分子生物学和生化产品的研究和製造，目标是提供基于重组 DNA 技术的医疗保健业务。

产品组合

Amgen 的溶瘤病毒治疗产品组合包括 IMLYGIC (talimogene laherparepvec)，一种单纯疱疹病毒 1 的减毒形式。

全球溶瘤病毒疗法市场报告将提供对大约 40 多个市场数据表、45 多个数字和 200 多页（大约）的访问。

内容

第一章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

• 市场影响因素
  • 驱动程序
    • 研发
    • 癌症患者增加
  • 约束因素
    • 高成本
    • 免疫反应
  • 商机
  • 影响分析

第五章行业分析

• 波特五力分析
• 供应链分析
• 监管分析
• 管道分析

第 6 章 COVID-19 分析

• COVID-19 的市场分析
  • COVID-19 之前的市场情景
  • COVID-19 的当前市场情景
  • COVID-19 后或未来情景
• COVID-19 期间的价格动态
• 供需范围
• 大流行期间与市场相关的政府举措
• 製造商的战略举措
• 总结

第 7 章按治疗类别

• Onxy-15
• Tarimo Genra Herpa Repbeck
• 重碱
• 吊钩
• 其他

第 8 章按应用程序

• 黑色素瘤
• 卵巢癌
• 乳腺癌
• 其他

第 9 章按治疗类型

• 使用 HSV 的溶瘤病毒
• 腺病毒肿瘤病毒
• 牛痘病毒抗癌剂
• 基于水疱性口炎病毒的溶瘤病毒
• 来源于新城疫病毒的溶瘤病毒

第 10 章按地区划分

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第 11 章竞争格局

• 主要发展和战略
• 公司份额分析
• 产品基准

第 12 章公司简介

• Amgen Inc.
  • 公司简介
  • 产品组合和描述
  • 主要亮点
  • 财务摘要
• Shanghai Sunway Biotech Co. Ltd
• RIGVIR

第 13 章数据M

Market Overview

Oncolytic Virus Therapy Market is expected to grow at a CAGR of 19.32% in the forecast period (2022-2029).

An oncolytic virus is a genetically engineered or naturally occurring virus that can imitate selected terms and kill cancer cells without harming normal tissues. Oncolytic Virus therapy is a new therapeutic approach for treating cancer and has shown promising results globally.

Market Dynamics

The rising prevalence of cancer cases and increasing development of cancer-treating therapies such as an oncolytic virus is driving the market growth globally.

The increasing number of cancer cases and clinical research propel the global oncolytic virus therapy market growth.

The growing cases of cancer and increasing clinical research on oncolytic virus therapy fuel the global market growth. For instance, according to the Clinical Trials. Gov, 10 interventional clinical studies are active; a few of them are Phase II window of opportunity trial of stereotactic body radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer and metastatic non-small cell lung cancer followed by Pembrolizumab sponsored by The Methodist Hospital Research Institute and estimated to be finished by November 2023, a phase I/II study of Pexa-Vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer sponsored by National Cancer Institute (NCI) and expected to be finished by June 2023 and a phase 1b & 2 study with GL-ONC1 oncolytic immunotherapy in patients with recurrent or refractory ovarian cancer (VIRO-15) sponsored by Genelux Corporation and completion date estimation is December 2022.

Furthermore, per the WHO statistics, cancer accounted for 10 million deaths in 2020, about 1 in 6 deaths from cancer. Out of which, around 70% of deaths occurred in low- and middle-income countries; the most common type of cancer are breast (2.26 million cases in 2020), lung (around 2.21 million cases in 2020), and colon & rectum cancers (1.93 million cases in 2020).

The high cost and immune reaction restrain the growth of the market.

The immune reaction to the virus-based therapies by repeated administration of therapeutics for treating cancer is a critical restraint hampering the market growth. The high cost of oncolytic virus therapy further affects market growth, especially in developing countries.

COVID-19 Impact

COVID-19 had a positive impact on the market by creating improved opportunities. For instance, COVID-19 has steered our focus towards biotechnologically modified products to achieve better results. Amidst the pandemic, many biopharmaceutical industries developed different biotechnologically modified vaccines to treat and diagnose SARS-CoV-2 to win over the pandemic. Moreover, biotechnological devices have helped in the various stages of fighting the pandemic; the COVID-19 pandemic has made us look at biotechnological solutions for a better healthcare system, which had an affirmative effect on the immunotoxin market.

Segment Analysis

The melanoma segment is assumed to command the global market throughout the forecast period (2022-2029).

Melanoma is expected to dominate the global market during the forecast period (2022-2029) owing to the growing burden of skin melanoma and new product approvals, such as FDA currently approved an oncolytic virus therapy for the treatment of skin melanoma, T-VEC (Imlygic), a modified herpes simplex virus (HSV) that infects tumor cells and promotes their destruction. Also, as per the WHO, annually 2 to 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally. One in every three cancers diagnosed is a skin cancer; according to Skin Cancer Foundation Statistics, one in every five Americans will develop skin cancer in their lifetime. As the ozone levels are depleted, the atmosphere loses more and more of its protective filter function, and more solar UV radiation reaches the Earth's surface. An estimated 10 percent decrease in ozone levels will result in an additional 300,000 non-melanoma and 4,500 melanoma skin cancer cases. According to the World Cancer Research Fund International, skin melanoma is the 17th most common cancer worldwide; there were more than 150,000 new melanoma cases in 2020. In reference to the Skin Cancer Foundation, in the U.S., more than 9,500 people are diagnosed with skin cancer every day.

Geographical Analysis

The North American region holds the largest global oncolytic virus therapy market.

North America dominated the global oncolytic skin cancer market in 2021. It is estimated to dominate throughout the forecast period (2022-2029) since there is a growing burden of cancer in this region, along with the increased focus and spending on research and development and the presence of key market players in North America. According to the National Cancer Institute, in 2020, 1,806,590 new cases were diagnosed, with 606,520 deaths registered of cancer. In addition, in 2021, around 1.9 million were diagnosed, and 608,570 deaths were confirmed of cancer, as per the American Cancer Society. According to the projection by CDC, new cancer cases per year will rise to 29.5 million by 2040. Moreover, North America has the most robust and advanced healthcare infrastructure, along with better healthcare cost reimbursement policies, which helps North America to dominate the global market during the forecast period.

Competitive Landscape

Oncolytic virus therapy is highly concentrated among a few key players, such as Amgen, Shanghai Sunway Biotech Co. Ltd, and RIGVIR. Companies in the industry operate on low-profit margins, which are likely to worsen further during the forecast period. Industry players are focusing on implementing inorganic growth strategies to expand their presence in the market. For instance, on 11 January 2022, Amgen and Arrakis Therapeutics collaborated to identify novel RNA degrader small molecule therapeutics.

Amgen Inc.

Overview:

Amgen Inc. is a leading multinational biopharmaceutical company founded in 1980 and headquartered in Thousand Oaks, California. Amgen Inc. is focused on research and manufacturing molecular biology and biochemistry products; its goal is to provide a healthcare business based on recombinant DNA technology.

Product Portfolio:

The product portfolio of Amgen Inc. for oncolytic virus therapy has IMLYGIC (talimogene laherparepvec) is a weakened form of Herpes Simplex Virus Type 1.

The global oncolytic virus therapy market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Research and Development
    • 4.1.1.2. Increasing Prevalence of Cancer Cases
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost
    • 4.1.2.2. Immune Reaction
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis
• 5.4. Pipeline Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Drug Class

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 7.1.2. Market Attractiveness Index, By Drug Class
• 7.2. Onxy-15
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Talimogene laherparepvec
• 7.4. Reolysin
• 7.5. RIGVIR
• 7.6. Others

8. By Applications

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Melanoma
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Ovarian Cancer
• 8.4. Breast Cancer
• 8.5. Others

9. By Therapy Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  • 9.1.2. Market Attractiveness Index, By Therapy Type
• 9.2. HSV-based Oncolytic Viruses
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Adenoviruses-based Oncolytic Viruses
• 9.4. Vaccinia Virus-based Oncolytic Viruses
• 9.5. Vesicular Stomatitis Virus-based Oncolytic Viruses
• 9.6. Newcastle Disease Virus-based Oncolytic Viruses

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Company Profiles

• 12.1. Amgen Inc.
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Shanghai Sunway Biotech Co. Ltd
• 12.3. RIGVIR

LIST NOT EXHAUSTIVE

13. DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us